Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion

International Journal of Cancer

Volumn 119, Issue 6, 2006, Pages 1481-1490

  Van Horssen, Remco ^a   Rens, Joost A P ^a   Brunstein, Flavia ^a   Guns, Veronique ^a   Van Gils, Marjon ^a   Ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

EMAP II; ILP patients; TNF R1

Indexed keywords

CD31 ANTIGEN; CD68 ANTIGEN; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; MELPHALAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ADVANCED CANCER; AGED; ANIMAL CELL; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENDOTHELIUM CELL; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; LIMB PERFUSION; MACROPHAGE; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SARCOMA; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYTOKINES; EXTREMITIES; FEMALE; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM PROTEINS; PERFUSION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA-BINDING PROTEINS; SARCOMA; SKIN NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33747450862     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21973     Document Type: Article

References (31)

1. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.
2. Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-β and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
3. Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben Ari G et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64.
4. Lejeune FJ, Lienard D, Eggermont AMM, Schraffordt Koops H, Rosenkaimer F, Gerain J, Klaase JM, Kroon BBR, Vanderveken J, Schmitz P. Rationale for using TNF α and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994;56:52-61.
5. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon β: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
6. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familletti PC, Wang F, Pan YC, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 1992;267:20239-47.
7. Murray JC, Clauss M, Denekamp J, Stern D. Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature. Int J Cancer 1991;49:254-9.
8. Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Bach R, Familletti PC, Stern D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 1990;265:7078-83.
9. Kao J, Fan YG, Haehnel I, Brett J, Greenberg S, Clauss M, Kayton M, Houck K, Kisiel W, Seljelid R, et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem 1994;269:9774-82.
10. Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, Grikscheit T, Chabot J, Nowygrod R, Greenberg S et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem 1994;269:25106-19.
11. Schwarz MA, Kandel J, Brett J, Li J, Hayward J, Schwarz RE, Chappey O, Wautier JL, Chabot J, Lo Gerfo P, Stern D. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 1999;190:341-54.
12. Murray JC, Symonds P, Ward W, Huggins M, Tiga A, Rice K, Heng YM, Todd I, Robins RA. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. J Immunol 2004;172:274-81.
13. Shalak V, Kaminska M, Mitnacht-Kraus R, Vandenabeele P, Clauss M, Mirande M. The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component. J Biol Chem 2001;276:23769-76.
14. Gnant MF, Berger AC, Huang J, Puhlmann M, Wu PC, Merino MJ, Bartlett DL, Alexander HR, Jr, Libutti SK. Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res 1999;59: 4668-74.
15. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-α is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999;59:205-12.
16. Berger AC, Alexander HR, Wu PC, Tang G, Gnant MF, Mixon A, Turner ES, Libutti SK. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). Cytokine 2000;12:992-1000.
17. Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 2005;30:347-58.
18. Lans TE, ten Hagen TL, van Horssen R, Wu PC, van Tiel ST, Libutti SK, Alexander HR, Eggermont AM. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. Ann Surg Oncol 2002;9:812-9.
19. WHO. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organisation, 1979.
20. Barnett G, Jakobsen AM, Tas M, Rice K, Carmichael J, Murray JC. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res 2000;60:2850-7.
21. Murray JC, Barnett G, Tas M, Jakobsen A, Brown J, Powe D, Clelland C. Immunohistochemical analysis of endothelial-monocyte-activating polypeptide-II expression in vivo. Am J Pathol 2000;157:2045-53.
22. Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple intransit metastases. Ann Surg 2004;240:939-47.
23. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM. EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:1801-6.
24. Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, Wallach D, Klausner J. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:650-9.
25. Gerain J, Lienard D, Pampallona S, Baumgartner M, Ruegg C, Buurman WA, Eggermont A, Lejeune F. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997;9:1034-42.
26. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, Straus SE, Lenardo MJ. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004;167:735-44.
27. Berger AC, Tang G, Alexander HR, Libutti SK. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. J Immunother 2000;23:519-27.
28. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
29. Tas MP, Murray JC. Endothelial-monocyte-activating polypeptide II. Int J Biochem Cell Biol 1996;28:837-41.
30. Jones SJ, Ledgerwood EC, Prins JB, Galbraith J, Johnson DR, Pober JS, Bradley JR. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999;162:1042-8.
31. Park SG, Shin H, Shin YK, Lee Y, Choi EC, Park BJ, Kim S. The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. Am J Pathol 2005;166:387-98.